T. Uchida

发表

Recovery from optic neuritis attack in neuromyelitis optica spectrum disorder and multiple sclerosis

M. Mori, A. Uzawa, M. Muto, 2016, Journal of the Neurological Sciences.

Relapse numbers and earlier intervention by disease modifying drugs are related with progression of less brain atrophy in patients with multiple sclerosis

M. Mori, A. Uzawa, S. Kuwabara, 2019, Journal of the Neurological Sciences.

Serum antinuclear antibody may be associated with less severe disease activity in neuromyelitis optica

M. Mori, A. Uzawa, M. Muto, 2016, European journal of neurology.

Recombinant thrombomodulin ameliorates experimental autoimmune encephalomyelitis by suppressing high mobility group box 1 and inflammatory cytokines

M. Mori, A. Uzawa, S. Kuwabara, 2018, Clinical and experimental immunology.

Seronegative neuromyelitis optica spectrum disorder patients diagnosed using new diagnostic criteria

M. Mori, A. Uzawa, S. Kuwabara, 2016, Multiple sclerosis.

Increased levels of CSF CD59 in neuromyelitis optica and multiple sclerosis.

M. Mori, A. Uzawa, S. Kuwabara, 2016, Clinica chimica acta; international journal of clinical chemistry.

Current symptomatology in multiple sclerosis and neuromyelitis optica

M. Mori, A. Uzawa, M. Muto, 2015, European journal of neurology.

Upbeat nystagmus at caudal brainstem lesions in four cases with multiple sclerosis and its related disorders

M. Mori, A. Uzawa, M. Muto, 2013 .

Difference in fatigue and pain between neuromyelitis optica spectrum disorder and multiple sclerosis

M. Mori, A. Uzawa, S. Kuwabara, 2020, PloS one.

Peroxiredoxins are involved in the pathogenesis of multiple sclerosis and neuromyelitis optica spectrum disorder

M. Mori, A. Uzawa, S. Kuwabara, 2020, Clinical and experimental immunology.

Soluble CD40 ligand contributes to blood–brain barrier breakdown and central nervous system inflammation in multiple sclerosis and neuromyelitis optica spectrum disorder

M. Mori, A. Uzawa, S. Kuwabara, 2017, Journal of Neuroimmunology.

Trigeminal root entry zone involvement in neuromyelitis optica and multiple sclerosis

M. Mori, A. Uzawa, M. Muto, 2015, Journal of the Neurological Sciences.

Anti-MOG antibody–associated disorders: differences in clinical profiles and prognosis in Japan and Germany

F. Paul, E. Meinl, J. Bellmann-Strobl, 2020, Journal of Neurology, Neurosurgery, and Psychiatry.

Clinical difference after the first optic neuritis between aquaporin-4-IgG-associated and myelin oligodendrocyte glycoprotein-IgG-associated disorders

M. Mori, A. Uzawa, M. Muto, 2021, Journal of Neurology.

Peripheral blood helper T cell profiles and their clinical relevance in MOG-IgG-associated and AQP4-IgG-associated disorders and MS

K. Sugimoto, M. Mori, A. Uzawa, 2019, Journal of Neurology, Neurosurgery, and Psychiatry.

Cerebrospinal fluid interleukin-6 and glial fibrillary acidic protein levels are increased during initial neuromyelitis optica attacks.

F. Nomura, M. Mori, A. Uzawa, 2013, Clinica chimica acta; international journal of clinical chemistry.

Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosis

M. Mori, A. Uzawa, S. Kuwabara, 2009, Journal of Neurology.

Interleukin-6 analysis of 572 consecutive CSF samples from neurological disorders: A special focus on neuromyelitis optica.

M. Mori, A. Uzawa, S. Kuwabara, 2017, Clinica chimica acta; international journal of clinical chemistry.

Randomized controlled study of postoperative adjuvant immunochemotherapy with Nocardia rubra cell wall skeleton (N-CWS) and Tegafur for gastric carcinoma

T. Tabuchi, A. Watanabe, S. Koyama, 2004, Cancer Immunology, Immunotherapy.

Serum soluble Talin-1 levels are elevated in patients with multiple sclerosis, reflecting its disease activity

K. Sugimoto, M. Mori, A. Uzawa, 2017, Journal of Neuroimmunology.

Elevated serum levels of bone morphogenetic protein-9 are associated with better outcome in AQP4-IgG seropositive NMOSD

M. Mori, A. Uzawa, M. Muto, 2023, Scientific Reports.

Gerstmann's Syndrome in a Patient Double-positive for Antibodies against the N-methyl-D-aspartate Receptor and NH2-terminal of α-enolase

S. Kuwabara, T. Suichi, T. Uchida, 2020, Internal medicine.

Comparison of brain atrophy in patients with multiple sclerosis treated with first‐ versus second‐generation disease modifying therapy without clinical relapse

M. Mori, A. Uzawa, S. Kuwabara, 2020, European journal of neurology.

Soluble CD40 ligand disrupts the blood–brain barrier and exacerbates inflammation in experimental autoimmune encephalomyelitis

M. Mori, A. Uzawa, S. Kuwabara, 2018, Journal of Neuroimmunology.

Silent progression of brain atrophy in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder

M. Mori, A. Uzawa, M. Muto, 2021, Journal of Neurology, Neurosurgery, and Psychiatry.

The accuracy of flow cytometric cell-based assay to detect anti-myelin oligodendrocyte glycoprotein (MOG) antibodies determining the optimal method for positivity judgement

T. Hiwasa, K. Sugimoto, M. Mori, 2019, Journal of Neuroimmunology.

Comparison of cognitive and brain grey matter volume profiles between multiple sclerosis and neuromyelitis optica spectrum disorder

N. Takahashi, M. Mori, A. Uzawa, 2017, PloS one.

Increased cerebrospinal fluid metalloproteinase-2 and interleukin-6 are associated with albumin quotient in neuromyelitis optica: Their possible role on blood–brain barrier disruption

M. Mori, A. Uzawa, M. Muto, 2017, Multiple sclerosis.

Peroxiredoxins are involved in the pathogenesis of multiple sclerosis and neuromyelitis optica spectrum disorder

M. Mori, A. Uzawa, S. Kuwabara, 2020, Clinical and experimental immunology.

Risk factors for fingolimod-induced lymphopenia in multiple sclerosis

M. Mori, A. Uzawa, S. Kuwabara, 2018, Multiple sclerosis journal - experimental, translational and clinical.

Validation of the Modified Fatigue Impact Scale and the relationships among fatigue, pain and serum interleukin-6 levels in patients with neuromyelitis optica spectrum disorder

M. Mori, A. Uzawa, S. Kuwabara, 2018, Journal of the Neurological Sciences.

Epstein-Barr virus persistence and reactivation in neuromyelitis optica

M. Mori, A. Uzawa, M. Muto, 2014, Journal of Neurology, Neurosurgery & Psychiatry.

Serum anti-JCV antibody indexes in Japanese patients with multiple sclerosis: elevations along with fingolimod treatment duration

M. Mori, A. Uzawa, S. Kuwabara, 2018, Journal of Neurology.

Validation of the Japanese version of the Modified Fatigue Impact Scale and assessment of the effect of pain on scale responses in patients with multiple sclerosis

M. Mori, A. Uzawa, M. Muto, 2015 .

Novel serum autoantibodies against talin1 in multiple sclerosis: Possible pathogenetic roles of the antibodies

Y. Iwadate, M. Takiguchi, T. Hiwasa, 2015, Journal of Neuroimmunology.

Cryptococcal Meningitis in a Fingolimod-Treated Patient: Positive Antigen Test a Year Before Onset.

M. Mori, A. Uzawa, S. Kuwabara, 2021, Neurology. Clinical practice.